To achieve this, a comprehensive understanding of the complex heterogeneity of pathways involved in KMT2A-r leukemogenesis and leukemia progression is warranted to allow identification of targetable vulnerabilities for each patient. This evidence concerns the gene KMT2A and leukemia.